[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"post-stroke-hemiparesis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:post-stroke-hemiparesis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,74,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100632440","estim-ul-fes-for-upper-limb-recovery-after-stroke-100632440",false,"NCT07513714","ESTIM-UL: FES for Upper Limb Recovery After Stroke","Efficacy of Functional Electrical Stimulation (FES) Combined With Task- Oriented Training on Upper Limb Recovery in Post-Stroke Patients With Spastic Hemiparesis: A Randomized Controlled Trial","ESTIM-UL","Inclusion Criteria:\n\n* Age 18 years or older.\n* Diagnosis of ischemic or hemorrhagic stroke, documented by CT or MRI.\n* Clinical presence of focal upper limb spasticity, defined as a score ≥ 1+ on the Modified Ashworth Scale (MAS) in at least one target muscle group (elbow, wrist, or finger flexors), treated with Botulinum Toxin Type A injection.\n* Presence of residual voluntary muscle activation (minimal active movement) sufficient to initiate the motor task required by the training (Box and Block score \\> 1).\n* Preserved cognitive function, defined as a Mini-Mental State Examination (MMSE) score ≥ 24 or clinical judgment confirming adequate comprehension and cooperation.\n\nExclusion Criteria:\n\n* Absolute contraindications to Functional Electrical Stimulation (FES), including the presence of a cardiac pacemaker or implantable cardioverter defibrillator (ICD), pharmacologically uncontrolled epilepsy, or skin lesions\u002Fdermatitis at the electrode application sites.\n* Presence of severe muscle-tendon contractures or fixed joint deformities (ankylosis) that mechanically limit passive movement and make active functional recovery unlikely.\n* Severe cognitive impairment, global aphasia, or severe unilateral spatial neglect that prevents task comprehension or active participation in the training program.\n* Concomitant orthopedic or rheumatologic conditions affecting the upper limb (e.g., recent fractures, severe arthritis) that could interfere with treatment delivery or outcome assessment.","ALL","18 Years","80 Years",{"count":21,"type":22},40,"ESTIMATED","INTERVENTIONAL",[25],"NA","Stroke is a leading cause of long-term disability, frequently resulting in impaired upper limb motor function and spasticity. Although Botulinum Toxin Type A (BoNT-A) is effective in reducing focal spasticity, functional recovery of the upper limb often remains limited without intensive, task-specific rehabilitation. Functional Electrical Stimulation (FES), when synchronized with voluntary movement during Task-Oriented Training, may enhance motor recovery by facilitating muscle activation and neuroplasticity. This randomized controlled trial aims to evaluate whether FES combined with Task-Oriented Training is superior to conventional Task-Oriented Training alone in improving upper limb function in post-stroke patients treated with BoNT-A.",[28,29,30],"Stroke","Post-Stroke Spasticity","Post-Stroke Hemiparesis",[32,33,34,35,36],"functional electrical stimulation","Botulinum Toxin Type A","stroke","motor recovery","upper limb","NOT_YET_RECRUITING","2026-03-30",{"date":40,"type":41},"2026-04-07","ACTUAL",{"date":43,"type":22},"2026-05-01",{"date":45,"type":22},"2026-12-01",{"name":47,"class":48},"University of Foggia","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":23,"phases":60,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":72,"locationsCount":49},"100607535","innovative-closed-loop-functional-electrical-stimulation-control-system-for-augmenting-post-stroke-gait-100607535","NCT07189819","Innovative Closed-loop Functional Electrical Stimulation Control System for Augmenting Post-stroke Gait","Inclusion Criteria:\n\n* \\>6 months since stroke\n* cortical or subcortical stroke\n* able to walk 10-meters with or without an assistive device\n* sufficient cardiovascular health and ankle stability to walk on treadmill without ankle orthosis\n* passive ankle range of motion to benefit from dorsiflexor FES assistance\n* resting heart rate 40-100 bpm\n\nExclusion Criteria:\n\n* cerebellar signs\n* score \\>1 on question 1b (does not know the current month and age) and \\>0 on question 1c (can not blink eyes and squeeze hands) on NIH Stroke Scale\n* inability to communicate with investigators\n* neglect\u002Fhemianopia\n* unexplained dizziness in past 6 months\n* sensory loss in paretic leg\n* musculoskeletal or medical conditions limiting walking\n* neurologic diagnoses other than stroke","40 Years","90 Years",{"count":59,"type":22},20,[25],"This study will compare the performance of a novel data-driven model-predictive controller (MPC) based functional electrical stimulation (FES) system versus a conventional FES system for footdrop correction during treadmill and overground walking tasks in people post-stroke.",[63],"Post-stroke Hemiparesis",[65],"post-stroke gait","2026-03-23",{"date":68,"type":41},"2026-03-25",{"date":70,"type":22},"2026-06-01",{"date":45,"type":22},{"name":73,"class":48},"Emory University",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":19,"enrollmentInfo":82,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":49},"100628197","tdcs-combined-with-constraint-induced-therapy-in-post-stroke-upper-limb-rehabilitation-100628197","NCT07458503","tDCS Combined With Constraint-Induced Therapy in Post-Stroke Upper Limb Rehabilitation","Effects of Transcranial Direct Current Stimulation Combined With Constraint-Induced Therapy on Upper Limb Motor Function in Individuals After Stroke: A Randomized Controlled Trial","tDCS-CIT Strok","Inclusion Criteria:\n\n* (1) present a clinical diagnosis of stroke confirmed by imaging examination and\u002For report issued by a neurologist; (2) are in the chronic phase of the lesion with an occurrence time greater than six months; (3) hemiparesis with brachial predominance, mild to moderate motor deficit in the affected upper limb defined by a score between 19 and 55 points on the FMA-UE; (4) have minimum joint integrity to perform the movements required in the protocol with an active range of motion of at least 20° of wrist extension, 10° of extension of the metacarpophalangeal and interphalangeal joints and 20° of elbow extension considering the standard position of 90° elbow flexion, measured with a Carci® goniometer; (5) demonstrate the ability to understand and follow simple commands on the Mini Mental State Examination (MMSE) (ANNEX II) with a score higher than 23 points for literate persons and lower than 15 points for illiterate persons.\n\nExclusion Criteria:(1) diagnosis of epilepsy; (2) intracranial metallic implants or implantable electronic devices; (3) contraindications to transcranial direct current stimulation (tDCS), including skin lesions on the scalp; (4) severe musculoskeletal limitations that prevent the execution of tasks; (5) history of recurrent stroke; (6) associated disabling musculoskeletal and neurological pathologies; (7) use of botulinum toxin in the previous three months; (8) uncontrolled systemic arterial hypertension or diabetes mellitus; (9) clinically relevant heart disease; (10) apraxia and aphasia of comprehension; (11) fracture and pain during movement or displacement of the affected limb, or pain related to shoulder subluxation. Those who feel uncomfortable, drop out of the research, do not respect the rules established in the Informed Consent Form (APPENDIX C), or do not attend the stages of the study will also be excluded.",{"count":21,"type":22},[25],"The objective of this clinical trial is to evaluate the effects of transcranial direct current stimulation (tDCS) combined with constraint-induced therapy (CIT) on upper limb motor recovery in individuals after stroke.\n\nThe main questions it aims to answer are:\n\nDoes the combination of tDCS and CIT improve upper limb motor function compared to CIT alone?\n\nDoes the combined intervention promote changes in muscle morphology and electromyographic activity?\n\nResearchers will compare the group receiving tDCS combined with constraint-induced therapy to the group receiving constraint-induced therapy alone to determine whether the addition of cortical neuromodulation enhances motor recovery outcomes.\n\nThis is a randomized, controlled, and blinded clinical trial in which participants will be divided into two groups: one group will receive tDCS combined with CIMT, and the other will undergo only CIMT. The protocol will include 18 sessions over six weeks, three times a week.\n\nClinical and instrumental assessments will be performed before, during, and after the intervention, including the Fugl-Meyer scale for the upper limb, musculoskeletal ultrasound for morphological analysis, and surface electromyography for muscle activity assessment.",[28,86,30],"Upper Limb Motor Impairment",[28,88,89],"Transcranial Direct Current Stimulation","Upper Limb","2026-03-03",{"date":92,"type":41},"2026-03-09",{"date":94,"type":22},"2026-04-15",{"date":96,"type":22},"2027-04-10",{"name":98,"class":48},"Universidade do Estado do Pará",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":23,"phases":108,"briefSummary":109,"conditions":110,"keywords":4,"overallStatus":113,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":5},"100569318","afo-prescription-to-optimize-post-stroke-function-100569318","NCT06692686","AFO Prescription to Optimize Post-Stroke Function","The Development of Patient-Centered Clinical AFO Prescription Guidelines to Optimize Post-Stroke Function and Quality of Life","Inclusion Criteria:\n\n* be a minimum of three months post-stroke\n* be greater than 18 years of age\n* have been prescribed either a semi-rigid or a custom-made articulating AFO\n* wear their prescribed AFO for all primary mobility activity outside the house\n* be able to walk at least 20 meters without manual assistance\n* walk at least 10 meters per minute (12% of normal velocity) during a 6-meter self-selected velocity walking test.\n\nExclusion Criteria:\n\n* having a condition that could significantly limit ambulation, including severe osteoarthritis, rheumatoid arthritis, congestive heart failure, or pre-existing neurological disorder other than post-stroke\n* having cognitive deficits that preclude their ability to provide consent for participation\n* having an ankle plantar flexion contracture equal to or greater than 15 degrees plantar flexion with full knee extension",{"count":107,"type":22},120,[25],"The overall goal of this study is to attain the highest possible health-related quality of life for individuals with lower-limb impairment through a clinical trial examining three different modern carbon fiber ankle-foot orthosis (AFO) treatment options targeting the rehabilitation of individuals post-stroke. To achieve this goal, the investigators will:\n\n1. Identify the factors that significantly contribute to an individual's highest potential quality of life when considering each of the three available AFO design options, and\n2. Develop prediction models of clinical performance using biomechanical function linked to the three AFO designs.\n\nParticipants will be asked to:\n\n* Wear each of the three modern AFO designs for one month, after receiving therapy training and\n* Complete questionnaires and performance tests with each AFO.\n\nIn addition, the subset of individuals participating in goal 2) will also be asked to:\n\n* Perform biomechanical analyses using high-speed cameras and force plates during different walking and balance tests with each AFO design.",[111,112,30],"Ankle Foot Orthosis (AFO)","Stroke Patients","RECRUITING","2025-08-15",{"date":116,"type":41},"2025-08-21",{"date":118,"type":41},"2025-07-08",{"date":120,"type":22},"2027-10",{"name":122,"class":48},"University of Texas at Austin"]